Zenitar
Latest round
- Series C
Last raised
- Jan 2026
Total raised
- $103M
Investors
- 16
About Zenitar
, trading as Zenitar is a biopharmaceutical research and development company dedicated to the drug research and development. It has acquired High-Tech Enterprise Certificate. It has 26 independent intellectual property rights and 24 patents., Ltd. The company R&D of new drug that includes tumors, autoimmune diseases, and cytokine storm caused by new coronavirus pneumonia. The company's disease research areas include B-cell related tumors, multiple myeloma, polycythemia vera, essential thrombocythemia. The company generates revenue by developing structural biology and artificial intelligence-driven medicines.
Who invested in Zenitar
16 investors across 4 rounds
See all investors in Zenitar
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Zenitar
Who invested in Zenitar?
Zenitar has 16 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Zenitar raised?
Zenitar has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Zenitar last raise money?
Zenitar's most recent round on record is a Series C, in Jan 2026.
What does Zenitar do?
, trading as Zenitar is a biopharmaceutical research and development company dedicated to the drug research and development.
Where is Zenitar headquartered?
Zenitar is headquartered in Chengdu, China.
Which VCs invest in companies like Zenitar?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Zenitar's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Zenitar? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.